Skip to main content

CLINICALLY MEANINGFUL RESULTS AND A DEMONSTRATED SAFETY PROFILE
IN ADULTS WITH BULLOUS PEMPHIGOID1

ADEPT was a phase 2/3
pivotal study that evaluated
DUPIXENT for sustained
disease remission, impact
on itch, and safety1-3

At Week 361

  • More patients achieved sustained remission with DUPIXENT + oral corticosteroid (OCS) taper vs placebo + OCS taper (18% vs 6%; primary endpoint; 95% CI: 12.2% [-0.8, 26.1])a
  • Clinically meaningful itch improvement in 38% vs 11% of patients, respectively (secondary endpoint; 95% CI: 27.8% [11.6, 43.4])b
  • Median cumulative dose of OCS at Week 36 was 2.8 g in patients treated with DUPIXENT vs 4.1 g with placebo

aThis data analysis for the primary endpoint did not meet statistical significance.

bDefinitive conclusions cannot be made for these results. Data were not multiplicity controlled.

VIEW DATA

Demonstrated long-term safety profile through Week 521,c

The most common adverse reactions (incidence ≥2%) in patients with bullous pemphigoid are arthralgia, conjunctivitis,
vision blurred, herpes viral infections, and keratitis.1

A case of acute generalized exanthematous pustulosis (AGEP) was reported in 1 subject with bullous pemphigoid treated with DUPIXENT compared with 0 subjects in the placebo group.1

cAt the time of safety analysis, 87 subjects had completed Week 36 and 65 subjects had completed Week 52.1

Dosing and administration

Thinking about prescribing DUPIXENT?
Find the information you need to get started.

Explore Administration Options